Update shared on15 Jul 2025
Fair value Decreased 13%The reduced analyst price target for NATCO Pharma reflects downgraded revenue growth forecasts and a lower future P/E, resulting in a fair value revision from ₹1133 to ₹972.09.
What's in the News
- Board meeting scheduled to consider and approve audited financial results for the quarter and year ended March 31, 2025, as well as other business matters.
Valuation Changes
Summary of Valuation Changes for NATCO Pharma
- The Consensus Analyst Price Target has significantly fallen from ₹1133 to ₹972.09.
- The Consensus Revenue Growth forecasts for NATCO Pharma has significantly fallen from -7.5% per annum to -10.1% per annum.
- The Future P/E for NATCO Pharma has significantly fallen from 40.07x to 35.28x.
Disclaimer
AnalystConsensusTarget is a tool utilizing a Large Language Model (LLM) that ingests data on consensus price targets, forecasted revenue and earnings figures, as well as the transcripts of earnings calls to produce qualitative analysis. The narratives produced by AnalystConsensusTarget are general in nature and are based solely on analyst data and publicly-available material published by the respective companies. These scenarios are not indicative of the company's future performance and are exploratory in nature. Simply Wall St has no position in the company(s) mentioned. Simply Wall St may provide the securities issuer or related entities with website advertising services for a fee, on an arm's length basis. These relationships have no impact on the way we conduct our business, the content we host, or how our content is served to users. The price targets and estimates used are consensus data, and do not constitute a recommendation to buy or sell any stock, and they do not take account of your objectives, or your financial situation. Note that AnalystConsensusTarget's analysis may not factor in the latest price-sensitive company announcements or qualitative material.